Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial.
Feldman AM, Oren RM, Abraham WT, Boehmer JP, Carson PE, Eichhorn E, Gilbert EM, Kao A, Leier CV, Lowes BD, Mathier MA, McGrew FA, Metra M, Zisman LS, Shakar SF, Krueger SK, Robertson AD, White BG, Gerber MJ, Wold GE, Bristow MR; EMOTE Study Group.
Feldman AM, et al. Among authors: mathier ma.
Am Heart J. 2007 Nov;154(5):861-9. doi: 10.1016/j.ahj.2007.06.044. Epub 2007 Sep 6.
Am Heart J. 2007.
PMID: 17967591
Clinical Trial.